In this episode of WND focusing on lung cancer, Prof Johan Vansteenkiste from University Hospitals Leuven and Prof Mariana Brandao, a medical oncologist at Institut Jules Bordet in Brussels, delve into the ALINA trial, which investigates the use of alectinib

In this episode of WND in lung cancer, Prof Johan Vansteenkiste from University Hospitals Leuven and Prof Mariana Brandao, a medical oncologist at Institut Jules Bordet in Brussels, discuss the results on tarlatamab in SCLC, as presented at ESMO2023.
It

In this episode of WND, Prof Johan Vansteenkiste from University Hospitals Leuven and Prof Mariana Brandao, a medical oncologist at Institut Jules Bordet in Brussels, present the highly anticipated OS results from the ADAURA trial.
The ADAURA trial focuses on

In this episode of WND, Prof Johan Vansteenkiste from University Hospitals Leuven and Prof Mariana Brandao, a medical oncologist at Institut Jules Bordet in Brussels, explore the optimal duration of immunotherapy for metastatic NSCLC patients.
Immunotherapy shows benefits across all

Since RET fusions are a rare subgroup, comprising less than 5% of NSCLC patients, this is a global phase 3 trial comparing the RET-specific TKI selpercatinib in the first line to the standard of care, initially chemotherapy and evolving to

Chemotherapy combined with immunotherapy yields superior results compared to chemotherapy alone in NSCLC patients. In the peri-operative setting this typically involves 3-4 cycles of chemotherapy plus immunotherapy followed by surgery, followed by one year of immunotherapy. Pathological complete response (pCR)

In this episode of WND on lung cancer, Professor Johan Vansteenkiste from University Hospitals Leuven and Professor Mariana Brandao, medical oncologist at Institut Jules Bordet in Brussels, will discuss the significant advancements in the EGFR field that have occurred over

In this episode of WND on lung cancer, Professor Johan Vansteenkiste from University Hospitals Leuven and Professor Mariana Brandao, medical oncologist at Institut Jules Bordet in Brussels, will discuss the KEYNOTE-671 trial regarding the addition of pembrolizumab in the peri-operative

This phase 3 trial randomized treatment-naïve NSCLC patients with classic EGFR mutations (ex19del or L858R) between SOC osimertinib and lazertinib, another third-generation EGFR TKI with excellent brain penetration, and a third arm combining amivantamab with lazertinib. Amivantamab is a novel

Professor Mariana Brandao, a medical oncologist at Institut Jules Bordet in Brussels, and Professor Johan Vansteenkiste from University Hospitals Leuven are pleased to announce a new episode of WND in lung cancer.
Immunotherapy has established itself as the standard for

Prof Mariana Brandao and Prof Johan Vansteenkiste discuss the FLAURA2 trial presented at WCLC2023, a recent study in EGFR-mutated NSCLC that holds clinical significance.

Osimertinib currently stands as the standard treatment for treatment-naïve patients with EGFR-mutated lung tumours, demonstrating high

In this first episode, Prof Mariana Brandao and Prof Johan Vansteenkiste engage in a discourse on the notable IMpower010 trial concerning adjuvant immunotherapy utilizing atezolizumab in patients with NSCLC.
Immunotherapy has profoundly transformed the management of metastatic and resectable lung